INO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Inovio Pharmaceuticals, Inc. Class Action

SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”).

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device

According to the complaint, during the class period, defendant failed to disclose that: (i) manufacturing for Inovio’s CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; and (iv) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated.

Plaintiff alleges that on August 8, 2024, Inovio issued a press release reporting its financial results and recent business highlights for the second quarter of 2024, revealing that Inovio expected to submit the INO-3107 BLA to the FDA in mid-2025—representing an approximate full-year delay from defendants’ initially projected mid-2024 submission timeline—because of “a manufacturing issue” with a component of the CELLECTRA device. On this news, Inovio’s stock price fell $0.27 per share, or 3.1%, to close at $8.44 per share on August 9, 2024.

Then, on December 29, 2025, Inovio issued a press release announcing that the FDA had accepted the INO-3107 BLA on a standard rather than accelerated review timeline. Because the Company did not submit adequate information to justify eligibility for accelerated approval. Defendants further advised that Inovio does not plan to seek approval under the standard review timeline and would request a meeting with the FDA to discuss how it may still pursue accelerated approval. On this news, Inovio’s stock price fell $0.56 per share, or 24.45%, to close at $1.73 per share on December 29, 2025.

What Now: You may be eligible to participate in the class action against Inovio Pharmaceuticals, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by April 7, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Inovio Pharmaceuticals, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.